TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Sunday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Down 3.6 %

Shares of TherapeuticsMD stock opened at $2.14 on Friday. TherapeuticsMD has a 52 week low of $1.84 and a 52 week high of $4.52. The company has a 50 day moving average price of $2.10 and a 200 day moving average price of $2.26.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.07) earnings per share for the quarter. The company had revenue of $0.31 million for the quarter.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC purchased a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned 0.21% of TherapeuticsMD as of its most recent filing with the SEC. 30.74% of the stock is currently owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.